Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Anna Rinewalt

Surgery Little Rock, AR Medical Doctor

NPI 1720289945 CMS profile 259581

108 N Shackleford Rd, Little Rock, AR 72211

Open in the dashboard

General payments

$6,969

57 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anna Rinewalt of Little Rock, AR is reported in the CMS Open Payments database as having received $6,969 across 57 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 74th percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,352 26
2024 General $63 3
2023 General $68 3
2022 General $102 6
2021 General $3,098 7
2020 General $153 7
2019 General $132 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anna Rinewalt
  • Surgery median
  • Middle half of Surgery
  • National median

In program year 2025, general payments to Anna Rinewalt were reported at $3,352. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.

Show as a table
Year Anna Rinewalt Surgery median Middle half National median
2019 $132 $253 $82–$1,521 $163
2020 $153 $131 $40–$706 $114
2021 $3,098 $168 $50–$904 $132
2022 $102 $224 $76–$1,218 $149
2023 $68 $253 $82–$1,255 $160
2024 $63 $279 $90–$1,381 $164
2025 $3,352 $280 $91–$1,259 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Southern Spine, LLC $3,000 1 payment
  2. Spinefrontier, Inc. $1,038 5 payments
  3. Globus Medical, Inc. $1,017 9 payments
  4. Stryker Corporation $953 7 payments
  5. Boston Scientific Corporation $234 3 payments
  6. Medtronic USA, Inc. $99 3 payments
  7. Xtant Medical Inc $93 1 payment
  8. Medtronic, Inc. $88 5 payments
  9. Avita Medical Americas, LLC $66 1 payment
  10. Allergan Inc. $53 3 payments
  11. Other $329 19 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $3,000 1 payment
  2. Travel and Lodging $2,239 7 payments
  3. Food and Beverage $1,730 49 payments
Products named General payments · program years 2019–2025
  1. Inspan $1,038 5 payments
  2. SIJFuse $1,038 5 payments
  3. FacetFuse $1,038 5 payments
  4. NanoFUSE $1,038 5 payments
  5. Senza $1,006 8 payments
  6. MILD DEVICE KIT $953 7 payments
  7. Intracept $215 2 payments
  8. INTELLIS Spinal Cord Neurostimulation $99 3 payments
  9. BOTOX $92 5 payments
  10. INTELLIS Spinal Cord Neurostimulation $54 3 payments
  11. Other $386 21 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

3,217

Median for General Surgery: 59

Drug cost

$60,852

Median for General Surgery: $393

Branded share of claims

42.8%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 826 $22,501
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 461 $11,527
Pregabalin Generic 253 $5,691
Gabapentin Generic 352 $4,530
Oxycodone Hcl Generic 292 $3,676
Fentanyl Generic 38 $2,850
Tizanidine Hcl Generic 285 $1,837
Morphine Sulfate Er Morphine Sulfate Brand 75 $1,683
Cyclobenzaprine Hcl Generic 151 $900
Buprenorphine Hcl Generic 22 $834

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$120,209

Medicare's payments for the services billed

Medicare patients

321

Average age 67

Services billed

1,586

218 women, 103 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 35%
Depression 33%
Chronic kidney disease 26%
Ischemic heart disease 25%
COPD 21%
Heart failure 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

57 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Surgery in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record